The European Medicines Agency (EMA), the US Food and Drug Administration (FDA) and Health Canada (HC) have agreed to establish a Rare Diseases Cluster (RDC) to facilitate the development of treatments for rare conditions by aligning regulatory expectations and sharing scientific expertise. The cluster, formalised in terms of reference dated 23 February 2026 and published by EMA on 17 July 2026, aims to address challenges such as small patient populations for clinical trials and the need to satisfy multiple regulatory authorities to reach a global market.
The cluster will serve as a forum for the three agencies to discuss regulatory science and policy barriers, with the primary goal of identifying common perspectives and understanding differences in expectations for drug development. Topics for discussion include trial endpoints, trial designs in small populations, regulatory flexibility (such as approval based on other than two adequate and well-controlled studies), safety populations, pre-clinical evidence, and post-marketing study designs, particularly in cases of accelerated or conditional approval. The cluster will also address long-term safety issues through confidential sharing of reports.
Participants from EMA include staff from Orphan medicines, Paediatric medicines, Regulatory Affairs, Scientific Advice, and International Affairs, with the Orphan medicines team providing the cluster secretariat. FDA participants will come from the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Office of Orphan Products Development (OOPD), and the Office of Paediatric Therapeutics (OPT). Health Canada will involve experts from the Biologics and Radiopharmaceutical Drugs Directorate (BRDD), the Pharmaceutical Drugs Directorate (PDD), and the Marketed Health Products Directorate (MHPD), with the Office of International Policy and Collaboration providing secretariat.
The cluster will hold monthly teleconferences, co-chaired by the three agencies, with the option for ad-hoc meetings on pressing product-related assessments. Observers from other regulatory authorities may participate subject to agreement and confidentiality arrangements. Topics that fall under other existing clusters—such as paediatric, oncology, pharmacovigilance, or advanced therapy medicinal products (ATMPs)—will be deferred to those platforms, with summaries shared back to the rare diseases cluster.
For stakeholders, the cluster is expected to benefit patients with rare diseases by potentially accelerating access to innovative treatments through more coordinated regulatory pathways. Pharmaceutical companies developing orphan drugs may face reduced duplication of efforts and clearer guidance, but could also encounter increased scrutiny as agencies align their expectations. National health authorities in the EU, US, and Canada may see improved consistency in regulatory decisions, though differences in legal frameworks may limit full harmonisation. The initiative represents a moderate step toward global regulatory convergence in a field where small patient numbers and high unmet need make international collaboration particularly valuable.